Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 3/20 | 0.50 |
| ▸ | CTSC | P53634 | 5/20 | 0.45 |
| ▸ | CDK1 | P06493 | 4/20 | 0.44 |
| ▸ | CCNK | O75909 | 1/20 | 0.44 |
| ▸ | CCND3 | P30281 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.43 |
| ▸ | ULK1 | O75385 | 2/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1933968 | 0.91 | SYK (0.51) | SYKCTSCCDK1PRKCQULK1 | |
| SCHEMBL2511679 | 0.89 | SYK (0.46) | SYKCTSCCDK1PRKCQULK1 | |
| SCHEMBL2510831 | 0.89 | SYK (0.46) | SYKCTSCCDK1PRKCQULK1 | |
| SCHEMBL2507979 | 0.86 | SYK (0.44) | SYKCTSCCDK1PRKCQAURKA | |
| SCHEMBL1917536 | 0.83 | CDK1 (0.59) | SYKCTSCCDK1PRKCQ | |
| SCHEMBL1935627 | 0.82 | SYK (0.47) | SYKCTSCCDK1PRKCQPTK2 | |
| SCHEMBL1917205 | 0.81 | KDR (0.56) | SYKCTSCCDK1PRKCQPTK2 | |
| SCHEMBL27850474 | 0.81 | ULK1 (0.60) | SYKCTSCCDK1ULK1AURKA | |
| SCHEMBL2508768 | 0.81 | SYK (0.54) | SYKCTSCCDK1PRKCQPTK2 | |
| SCHEMBL1916571 | 0.80 | GSK3A (0.56) | SYKCTSCCDK1CDK9AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230478-A1 | 4-Alkyl-substituted diaminopyrimidines | Bayer ScienceCrop AG (DE) | 2011-09-22 | — | — | US | disclosed |
| EP-2330904-A2 | 4-ALKYL-SUBSTITUTED DIAMINOPYRIMIDINES | Bayer CropScience AG (DE) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010025863-A2 | 4-ALKYL-SUBSTITUTED DIAMINOPYRIMIDINES | BAYER CROPSCIENCE AG (DE) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230478-A1 | 4-Alkyl-substituted diaminopyrimidines | DPM1, DPYD, POLR1C | SYK 1469/4885CTSC 2436/4885CDK1 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.